Previous 10 | Next 10 |
Evidence of improvement in vision and retinal structure in patients with DME and AMD sustained through 12 weeks Sustained responses following single treatment with UBX1325 support durability of senolytic therapeutic approach; data builds on previously reported results at 8 weeks...
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will present at the upcoming...
UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD) Results from Phase 1 study of UBX1325 in a...
Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325 PR Newswire SUZHOU, China , and ROCKVILLE, Md. , July 28, 2021 /PRNewswire/ -- ...
I recently covered Unity's transition away from its failed osteoarthritis program to its ophthalmology program focused on retinal diseases. UBX1325 had posted strong preclinical results that suggested senescent cells might actually be causally involved in various retinal disease patho...
UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325 UNITY to host conference call on July 27, 2021, at 8:00 a.m. PT (11:00 a.m. ET) SOUTH ...
8 Hot Penny Stocks to Watch After the Holiday Weekend As investors return to work following the long weekend, which penny stocks are showing momentum right now? Well, there are quite a few industries that are in mind in early July 2021. And to understand which, traders need to take a de...
Weibo WB +43% on report that Chairman Chao, investor in talks for at least $20B buyout.Bridgeline Digital (BLIN) +35%.BSQUARE (BSQR) +32%.Marin Software (MRIN) +26%.Axcella Health (AXLA) +23%.Odonate Therapeutics (ODT) +21%.Ocugen OCGN +19% Shares extended gains after part...
Shidlovski/iStock via Getty Images UNITY Biotechnology (UBX) has added ~13.0% in the pre-market after the company announced promising early-stage data for UBX1325 in patients with diabetic macular edema ((DME)) or wet age-related macular degeneration ((wet AMD)). The phase...
Improvement in Visual Acuity and Central Subfield Thickness observed in diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) patients treated with UBX1325 UBX1325 advances to Phase 2a study in DME patients as a potential alternative to anti-VEGF therap...
News, Short Squeeze, Breakout and More Instantly...
Unity Biotechnology Inc. Company Name:
UBX Stock Symbol:
NASDAQ Market:
Unity Biotechnology Inc. Website:
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. "Our team r...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at t...
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the ongoing Phase 2b ASPIRE study of UBX1325 has been e...